bi huang

Dr. bi huang

The First Affiliated Hospital of Chongqing Medical University

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2025 in Redox Biology
Verified
Journal Article
Open access
YCYang Chen
Yang Chen
SWShuang Wu
Shuang Wu
HLHongyu Liu
Hongyu Liu
ZZZiyi Zhong
Ziyi Zhong
TBTommaso Bucci
Tommaso Bucci
Gregory LipGregory Lip
Gregory Lip
To evaluate the roles of oxidative balance score (OBS) in staging and mortality risk of cardiovascular-kidney-metabolic syndrome (CKM). Data of this study were from the National Health and Nutrition Examination Survey 1999-2018. We performed cross-sectional analyses using multinomial logistic regression to investigate the relationship between OBS and CKM staging. Cox proportional hazards models were used to assess the impact of OBS on mortality outcomes in CKM patients. Additionally, mediation analyses were performed to explore whether OBS mediated the relationships between specific predictors (Life's Simple 7 score [LS7], systemic immune-inflammation index [SII], frailty score) and mortality outcomes. Then, machine learning models were developed to classify CKM stages 3/4 and predict all-cause mortality, with SHapley Additive exPlanations values used to interpret the contribution of OBS components. 21,609 participants were included (20,319 CKM, median [IQR] age: 52.0 [38.0-65.0] years, 54.3% male, median [IQR] follow-up: 9.4 [5.3-14.1] years). Lower OBS quartiles were associated with advanced CKM staging. Moreover, lower OBS quartiles were related to increased mortality risk, compared to Q4 of OBS (all-cause mortality: Q1: HR 1.31, 95% CI 1.18-1.46, Q2: HR 1.27, 95% CI 1.14-1.42, Q3: HR 1.18, 95% CI 1.06-1.32; cardiovascular mortality: Q1: HR 1.44, 95% CI 1.16-1.79, Q2: HR 1.39, 95% CI 1.11-1.74, Q3: HR 1.26, 95% CI 1.01-1.57; non-cardiovascular mortality, Q1: HR 1.27, 95% CI 1.12-1.44, Q2: HR 1.23, 95% CI 1.08-1.40, Q3: HR 1.16, 95% CI 1.02-1.31), with optimal risk stratification threshold for OBS was 22. Additionally, OBS mediated (ranging 4.25%-32.85 %) effects of SII, LS7, frailty scores on mortality outcomes. Moreover, light gradient boosting machine achieved the highest performance for predicting advanced CKM staging (area under curve: 0.905) and all-cause mortality (area under curve: 0.875). Cotinine increased risk, while magnesium, vitamin B6, physical activity were protective. This study highlights OBS as a risk stratification tool for CKM, emphasizing oxidative stress's role in CKM staging and mortality risk management.

1 January 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
YZYuansong Zhu
Yuansong Zhu
BSBryan Richard Sasmita
Bryan Richard Sasmita
XHXiankang Hu
Xiankang Hu
YXYuzhou Xue
Yuzhou Xue
HGHongbo Gan
Hongbo Gan
SLSu Xin Luo
Su Xin Luo
Purpose. Cardiogenic shock (CS) is the leading cause of death in patients with acute myocardial infarction (AMI). Our study aimed to evaluate the short‐term prognostic value of admission blood urea nitrogen (BUN) in patients with CS complicating AMI. Materials and Methods. 218 consecutive patients with CS after AMI were enrolled. The primary endpoint was 30‐day mortality. The association of admission BUN and 30‐day mortality and major adverse cardiovascular event (MACE) was investigated by Cox regression. The integrated discrimination improvement (IDI) and net reclassification improvement (NRI) further examined the predictive value of BUN. Results. During a period of 30‐day follow‐up, 105 deaths occurred. Compared to survivors, nonsurvivors had significantly higher admission BUN (p < 0.001), creatinine (p < 0.001), BUN/creatinine (p = 0.03), and a lower glomerular filtration rate (p < 0.001). The area under the curve (AUC) of the 4 indices for predicting 30‐day mortality was 0.781, 0.734, 0.588, and 0.773, respectively. When compared to traditional markers associated with CS, the AUC for predicting 30‐day mortality of BUN, lactate, and left ventricular ejection fraction were 0.781, 0.776, and 0.701, respectively. The optimal cut‐off value of BUN for predicting 30‐day mortality was 8.95 mmol/L with Youden‐Index analysis. Multivariate Cox analysis indicated BUN >8.95 mmol/L was an important independent predictor for 30‐day mortality (HR 2.08, 95%CI 1.28–3.36, p = 0.003) and 30‐day MACE (HR 1.85, 95%CI 1.29–2.66, p = 0.001). IDI (0.053, p = 0.005) and NRI (0.135, p = 0.010) showed an improvement in the accuracy for mortality prediction of the new model when BUN was included compared with the standard model of predictors in previous scores. Conclusion. An admission BUN >8.95 mmol/L was robustly associated with increased short‐term mortality and MACE in patients with CS after AMI. The prognostic value of BUN was superior to other renal markers and comparable to traditional markers. This easily accessible index might be promising for early risk stratification in CS patients following AMI.

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
DLDingyi Lv
Dingyi Lv
MINGHAO LUOMINGHAO LUO
MINGHAO LUO
ZCZhe Cheng
Zhe Cheng
RWRuiyu Wang
Ruiyu Wang
XYXiyang Yang
Xiyang Yang
JYJianghong Yan
Jianghong Yan
Myocardial ischemia‐reperfusion injury (MIRI) is a phenomenon that reperfusion leads to irreversible damage to the myocardium and increases mortality in acute myocardial infarction (AMI) patients. There is no effective drug to treat MIRI. Tubeimoside I (TBM) is a triterpenoid saponin purified from Chinese traditional medicine tubeimu. In this study, 4 mg/kg TBM was given to mice intraperitoneally at 15 min after ischemia. And TBM treatment improved postischemic cardiac function, decreased infarct size, diminished lactate dehydrogenase release, ameliorated oxidative stress, and reduced apoptotic index. Notably, ischemia‐reperfusion induced a significant decrease in cardiac SIRT3 expression and activity, while TBM treatment upregulated SIRT3’s expression and activity. However, the cardioprotective effects of TBM were largely abolished by a SIRT3 inhibitor 3‐(1H‐1,2,3‐triazol‐4‐yl) pyridine (3‐TYP). This suggests that SIRT3 plays an essential role in TBM’s cardioprotective effects. In vitro, TBM also protected H9c2 cells against simulated ischemia/reperfusion (SIR) injury by attenuating oxidative stress and apoptosis, and siSIRT3 diminished its protective effects. Taken together, our results demonstrate for the first time that TBM protects against MIRI through SIRT3‐dependent regulation of oxidative stress and apoptosis. TBM might be a potential drug candidate for MIRI treatment.

8 April 2010 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
KLK. Liu
K. Liu
DZD. Zai
D. Zai
DZD. Zhang
D. Zhang
QWQ. Wei
Q. Wei
GHG. Han
G. Han
BHbi huang
bi huang

28 July 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
BSBryan Richard Sasmita
Bryan Richard Sasmita
YZYuansong Zhu
Yuansong Zhu
HGHongbo Gan
Hongbo Gan
XHXiankang Hu
Xiankang Hu
YXYuzhou Xue
Yuzhou Xue
SLSuxin Luo
Suxin Luo

18 January 2024 in Global Heart
Verified
Journal Article
Open access
PDF file
BSBryan Richard Sasmita
Bryan Richard Sasmita
YZYuhe Zhao
Yuhe Zhao
MGMing Gong
Ming Gong
SLSu Xin Luo
Su Xin Luo
BHbi huang
bi huang
Introduction: Chronic fluid accumulation or congestion is considered an important pathophysiologic mechanism in heart failure, leading to cardinal symptoms such as dyspnea, pulmonary congestion, and pitting edema. Edema index (EI) recently emerged as a surrogate for extracellular volume status and has been proven to be able to reflect one’s congestion status. In this study, we aimed to evaluate the prognostic value of EI in patients with chronic heart failure (CHF). Methods: A total of 401 consecutive patients with CHF between August 2019 and October 2021 were prospectively enrolled. EI was obtained by InBody S10. The primary endpoint was long-term all-cause and cardiovascular mortality. Results: Patients with high EI (>0.397) tended to be older, presented with atrial fibrillation, have higher N-terminal brain natriuretic peptide, and have higher creatinine (all p < 0.05). During a median follow-up of 1200 days, the all-cause and cardiovascular mortality rate was significantly higher in the high EI group compared to the low EI group (all-cause mortality rate 43.8% vs. 30.3%, p < 0.001, and cardiovascular mortality rate 17.5% vs. 13.0%, p < 0.001, respectively). In the multivariate Cox proportional hazard analysis, EI > 0.397 was an independent predictor for both all-cause mortality (HR 1.959; 95% CI 1.304, 2.944; p = 0.001) and cardiovascular mortality (HR 2.051; 95% CI 1.276, 3.296; p = 0.003). Conclusions: Admission EI could be used as a marker for predicting long-term mortality in patients with CHF, and higher EI was associated with an increased risk of all-cause and cardiovascular mortality. Furthermore, EI-guided management could be a promising therapy in patients with CHF.